Grant Programs, Expanded Product Portfolios, Conference Presentations, Earnings Results, and Dividend Authorizations - Analyst Notes on Covidien, Waters, Cooper, Mindray and West Pharmaceutical

NEW YORK, May 28, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Waters Corp. (NYSE: WAT), The Cooper Companies Inc. (NYSE: COO), Mindray Medical International Limited (NYSE: MR) and West Pharmaceutical Services, Inc. (NYSE: WST). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2999-100free.

--
Covidien plc Analyst Notes
On May 19, 2014, Covidien plc (Covidien) together with the National Association of Community Health Centers (NACHC) announced the recipients of the 2014 Covidien Challenge Grant program which aims to help bring quality healthcare to underserved populations in hundreds of communities. A total of 24 communities received challenge grants totaling more than $1 million, which according to the Company, will enable the centers access additional grants and other untapped sources of private funds for small- to mid-level capital improvement projects. "This partnership supports our commitment to increase access to quality, affordable healthcare by helping to meet the growing health needs of communities and the people they serve," said Michael Tarnoff, M.D., Global Chief Medical officer, Covidien. "By partnering with NACHC we are able to help provide quality health care to communities across the U.S. while reducing the need for costly emergency room care." Further, the collaboration of Covidien and NACH will also identify other national programs to benefit community health centers. The full analyst notes on Covidien are available to download free of charge at:

http://www.analystsreview.com/COV.pdf/Register

--
Waters Corp. Analyst Notes
On May 12, 2014, Waters Corp. (Waters) announced the introduction of CORTECS 2.7 Micron Columns, the newest addition to the family of Waters® CORTECS Columns. The Company informed that the new line of 2.7 micron silica-based, solid-core particle columns is specifically designed for analytical scientists who need to maximize performance on their existing LC systems. Also, Waters informed that CORTECS 2.7 micron Columns run at lower pressures while delivering high efficiencies, giving the scientist the flexibility to use longer column lengths to improve resolution or higher flow rates to speed instrument analysis times and increase throughput. "With the introduction of CORTECS 2.7 micron Columns, Waters now gives chromatographic laboratories the ability to improve the resolution, speed, and sensitivity of their HPLC separations," said Michael Yelle, Vice President, Consumables Business Unit, Waters Division. "The advanced solid-core particle design of CORTECS 2.7 micron Columns together with Waters' 40+ years of column manufacturing expertise put these columns at the head of their class in terms of overall chromatographic performance with the market leading batch-to-batch reproducibility, robustness and quality our customers have come to expect from Waters." The full analyst notes on Waters are available to download free of charge at:

http://www.analystsreview.com/WAT.pdf/Register

--
The Cooper Companies Inc. Analyst Notes
On May 22, 2014, The Cooper Companies, Inc. (Cooper) announced that it will be presenting at the 34th Annual Growth Stock Conference. Cooper informed that the conference will be held in Chicago, Illinois on June 12, 2014, and Greg W. Matz, Vice President, CFO & CRO (Chief Risk Officer), will present on behalf of the Company. The presentation is scheduled to begin at 10:20 a.m. ET. Cooper also informed that a live audio webcast of the presentation will be available at the Investor Relations section of its website. The full analyst notes on Cooper are available to download free of charge at:

http://www.analystsreview.com/COO.pdf/Register

--
Mindray Medical International Limited Analyst Notes
On May 5, 2014, Mindray Medical International Limited (Mindray) reported its unaudited Q1 2014 financial results. The Company reported revenues of $264.8 million, up 9.4% YoY. Operating income totaled $31.3 million, down 19.8% YoY, while net income totaled $35.6 million, down 37.9% YoY. Diluted EPS for the quarter came in at $0.30 compared to $0.48 in Q1 2013. "In the first quarter, the dynamics in various key markets continued to be challenging for our business. Nevertheless, we are pleased with our Western Europe performance, as well as our IVD reagent sales year-over-year increase," commented Mr. Li Xiting, Mindray's President and Co-CEO. The Company anticipates annual net revenue growth of 15% YoY and capital expenditure to be around $160 million for full year 2014. The full analyst notes on Mindray are available to download free of charge at:

http://www.analystsreview.com/MR.pdf/Register

--
West Pharmaceutical Services, Inc. Analyst Notes
On May 8, 2014, West Pharmaceutical Services, Inc. (West Pharmaceutical) announced that its Board of Directors has authorized and declared a quarterly dividend in the amount of $0.10 per share for Q3 FY 2014. The dividend will be paid on August 6, 2014 to shareholders of record on July 23, 2014. The full analyst notes on West Pharmaceutical are available to download free of charge at:

http://www.analystsreview.com/WST.pdf/Register

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED